肠道微生态与结直肠癌发生发展的关系

doi:10.3760/cma.j.cn371439-20251119-00060

国际肿瘤学杂志 ›› 2026, Vol. 53 ›› Issue (6): 370-375.doi: 10.3760/cma.j.cn371439-20251119-00060

肠道微生态与结直肠癌发生发展的关系

王勇¹, 赵海燕², 张明明³, 乌新林⁴()

¹ 内蒙古医科大学第一临床医学院，呼和浩特 010050
² 内蒙古医科大学附属医院肿瘤内科，呼和浩特 010050
³ 内蒙古准格尔旗中心医院胃肠、泌尿（疝）外科，准格尔旗 010300
⁴ 内蒙古医科大学附属医院胃肠外科，呼和浩特 010050

收稿日期:2025-11-19 出版日期:2026-06-08 发布日期:2026-06-05
通讯作者: 乌新林，Email：wuxinlin@126.com
基金资助:
内蒙古医学科学院公立医院科研联合基金科技项目(2024GLLH0300);内蒙古自治区科技计划(2025YFHH0192)

Relationship between intestinal microecology and the occurrence and progression of colorectal cancer

Wang Yong¹, Zhao Haiyan², Zhang Mingming³, Wu Xinlin⁴()

¹ First Clinical College of Inner Mongolia Medical University， Hohhot 010050， China
² Department of Medical Oncology， Affiliated Hospital of Inner Mongolia Medical University， Hohhot 010050， China
³ Department of Gastrointestinal， Urinary and Hernia Surgery，Jungar Banner Central Hospital of Inner Mongolia， Jungar Banner 010300， China
⁴ Department of Gastrointestinal Surgery， Affiliated Hospital of Inner Mongolia Medical University， Hohhot 010050， China

Received:2025-11-19 Online:2026-06-08 Published:2026-06-05
Contact: Wu Xinlin，Email：wuxinlin@126.com
Supported by:
Science and Technology Program of the Joint Fund of Scientific Research for the Public Hospitals of Inner Mongolia Academy of Medical Sciences(2024GLLH0300);Science and Technology Program Project of Inner Mongolia Autonomous Region of China(2025YFHH0192)

摘要/Abstract

摘要：

肠道微生态由肠道微生物及其代谢产物组成，与结直肠癌发生、发展密切相关。肠道微生物中，具核梭杆菌、产肠毒素脆弱拟杆菌、pks⁺大肠杆菌等细菌，热带念珠菌、白色念珠菌等真菌，以及相关病毒，均可通过不同机制促进结直肠癌的发生发展。微生物代谢产物在结直肠癌的发生发展中具有双向作用，丁酸、吲哚-3-乳酸、熊脱氧胆酸等发挥抑癌作用，甲酸、吲哚-3-丙烯酸、脱氧胆酸等则发挥促癌作用。深入分析肠道微生态的功能与作用机制，可为结直肠癌的相关基础研究与临床诊疗提供理论参考。

关键词: 结直肠肿瘤, 胃肠道微生物组, 免疫调节

Abstract:

The intestinal microecology consists of intestinal microorganisms and their metabolites，and is closely related to the occurrence and development of colorectal cancer. Among intestinal microorganisms，bacteria such as fusobacterium nucleatum，entero toxigenic bacteroides fragilis，and pks⁺ escherichia coli； and fungi such as candida tropicalis and candida albicans； as well as related viruses，can promote the occurrence and development of colorectal cancer through different mechanisms. Microbial metabolites exert a bidirectional effect in the occurrence and development of colorectal cancer：butyric acid，indole-3-lactic acid，ursodeoxycholic acid，etc.，play tumor-suppressive roles，while formic acid，indole-3-acrylic acid，deoxycholic acid，etc.，exert tumor-promoting effects. In-depth analysis of the functions and mechanisms of the intestinal microecology can provide theoretical references for related basic research and clinical diagnosis and treatment of colorectal cancer.

Key words: Colorectal neoplasms, Gastrointestinal microbiome, Immunomodulation

王勇, 赵海燕, 张明明, 乌新林. 肠道微生态与结直肠癌发生发展的关系[J]. 国际肿瘤学杂志, 2026, 53(6): 370-375.

Wang Yong, Zhao Haiyan, Zhang Mingming, Wu Xinlin. Relationship between intestinal microecology and the occurrence and progression of colorectal cancer[J]. Journal of International Oncology, 2026, 53(6): 370-375.

参考文献 41

[1]	Bray F, Laversanne M, Sung H, et al. Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries[J]. CA Cancer J Clin, 2024, 74(3): 229-263. DOI: 10.3322/caac.21834.
[2]	郑荣寿, 陈茹, 韩冰峰, 等. 2022年中国恶性肿瘤流行情况分析[J]. 中华肿瘤杂志, 2024, 46(3): 221-231. DOI: 10.3760/cma.j.cn112152-20240119-00035.
[3]	Yadav A, Ahlawat S, Sharma KK. Culturing the unculturables: strategies, challenges, and opportunities for gut microbiome study[J]. J Appl Microbiol, 2023, 134(12): lxad280. DOI: 10.1093/jambio/lxad280.
[4]	Pignatelli P, Nuccio F, Piattelli A, et al. The role of fusobacterium nucleatum in oral and colorectal carcinogenesis[J]. Microorganisms, 2023, 11(9): 2358. DOI: 10.3390/microorganisms11092358.
[5]	Galasso L, Termite F, Mignini I, et al. Unraveling the role of fusobacterium nucleatum in colorectal cancer: molecular mechanisms and pathogenic insights[J]. Cancers (Basel), 2025, 17(3): 368. DOI: 10.3390/cancers17030368.
[6]	Dadgar-Zankbar L, Elahi Z, Shariati A, et al. Exploring the role of fusobacterium nucleatum in colorectal cancer: implications for tumor proliferation and chemoresistance[J]. Cell Commun Signal, 2024, 22(1): 547. DOI: 10.1186/s12964-024-01909-y. pmid: 39548531
[7]	Zhu YY, Li X. Advances of WNT signalling pathway in colorectal cancer[J]. Cells, 2023, 12(3): 447. DOI: 10.3390/cells12030447.
[8]	Yu YL, Yin H, Wu BB, et al. Fusobacterium nucleatum promotes colorectal cancer liver metastasis via miR-5692a/IL-8 axis by inducing epithelial-mesenchymal transition[J]. J Biomed Sci, 2025, 32: 5. DOI: 10.1186/s12929-024-01097-4. pmid: 39757156
[9]	Scott N, Whittle E, Jeraldo P, et al. A systemic review of the role of enterotoxic bacteroides fragilis in colorectal cancer[J]. Neoplasia, 2022, 29: 100797. DOI: 10.1016/j.neo.2022.100797.
[10]	Lee CG, Hwang S, Gwon SY, et al. Bacteroides fragilis toxin induces intestinal epithelial cell secretion of interleukin-8 by the E-cadherin/β-catenin/NF-κB dependent pathway[J]. Biomedicines, 2022, 10(4): 827. DOI: 10.3390/biomedicines10040827.
[11]	Cao YY, Wang ZH, Yan YQ, et al. Enterotoxigenic bacteroidesfragilis promotes intestinal inflammation and malignancy by inhibiting exosome-packaged miR-149-3p[J]. Gastroenterology, 2021, 161(5): 1552-1566.e12. DOI: 10.1053/j.gastro.2021.08.003.
[12]	Dziubańska-Kusibab PJ, Berger H, Battistini F, et al. Colibactin DNA-damage signature indicates mutational impact in colorectal cancer[J]. Nat Med, 2020, 26(7): 1063-1069. DOI: 10.1038/s41591-020-0908-2. pmid: 32483361
[13]	Iftekhar A, Berger H, Bouznad N, et al. Genomic aberrations after short-term exposure to colibactin-producing E. coli transform primary colon epithelial cells[J]. Nat Commun, 2021, 12(1): 1003. DOI: 10.1038/s41467-021-21162-y. pmid: 33579932
[14]	Richard ML, Sokol H. The gut mycobiota: insights into analysis, environmental interactions and role in gastrointestinal diseases[J]. Nat Rev Gastroenterol Hepatol, 2019, 16(6): 331-345. DOI: 10.1038/s41575-019-0121-2. pmid: 30824884
[15]	Zhang ZY, Chen Y, Pan XY, et al. IL-1β mediates candida tropicalis-induced immunosuppressive function of MDSCs to foster colorectal cancer[J]. Cell Commun Signal, 2024, 22(1): 408. DOI: 10.1186/s12964-024-01771-y. pmid: 39164774
[16]	Zhang ZY, Zheng YJ, Chen Y, et al. Gut fungi enhances immunosuppressive function of myeloid-derived suppressor cells by activa-ting PKM2-dependent glycolysis to promote colorectal tumorigenesis[J]. Exp Hematol Oncol, 2022, 11(1): 88. DOI: 10.1186/s40164-022-00334-6.
[17]	Zhu YN, Shi T, Lu X, et al. Fungal-induced glycolysis in macrophages promotes colon cancer by enhancing innate lymphoid cell secretion of IL-22[J]. EMBO J, 2021, 40(11): e105320. DOI: 10.15252/embj.2020105320.
[18]	Ost KS, O'Meara TR, Stephens WZ, et al. Adaptive immunity induces mutualism between commensal eukaryotes[J]. Nature, 2021, 596(7870): 114-118. DOI: 10.1038/s41586-021-03722-w.
[19]	Pérez JC. The interplay between gut bacteria and the yeast candida albicans[J]. Gut Microbes, 2021, 13(1): 1979877. DOI: 10.1080/19490976.2021.1979877.
[20]	Fong JL, Ong Eng Yong V, Yeo C, et al. Biochemical characterization of recombinant enterococcus faecalis EntV peptide to elucidate its antihyphal and antifungal mechanisms against candida albicans[J]. ACS Infect Dis, 2024, 10(9): 3408-3418. DOI: 10.1021/acsinfecdis.4c00515. pmid: 39137394
[21]	Guinan J, Wang SH, Hazbun TR, et al. Antibiotic-induced decreases in the levels of microbial-derived short-chain fatty acids correlate with increased gastrointestinal colonization of candida albicans[J]. Sci Rep, 2019, 9(1): 8872. DOI: 10.1038/s41598-019-45467-7. pmid: 31222159
[22]	Lindstad LJ, Lo G, Leivers S, et al. Human gut faecalibacterium prausnitzii deploys a highly efficient conserved system to cross-feed on β-mannan-derived oligosaccharides[J]. mBio, 2021, 12(3): e0362820. DOI: 10.1128/mBio.03628-20.
[23]	Pei ZM, Liu YF, Chen YT, et al. A universe of human gut-derived bacterial prophages: unveiling the hidden viral players in intestinal microecology[J]. Gut Microbes, 2024, 16(1): 2309684. DOI: 10.1080/19490976.2024.2309684.
[24]	Ralser A, Dietl A, Jarosch S, et al. Helicobacter pylori promotes colorectal carcinogenesis by deregulating intestinal immunity and inducing a mucus-degrading microbiota signature[J]. Gut, 2023, 72(7): 1258-1270. DOI: 10.1136/gutjnl-2022-328075. pmid: 37015754
[25]	Luo SQ, Ru JL, Mirzaei MK, et al. Gut virome profiling identifies an association between temperate phages and colorectal cancer promoted by helicobacter pylori infection[J]. Gut Microbes, 2023, 15(2): 2257291. DOI: 10.1080/19490976.2023.2257291.
[26]	Cong JJ, Liu PP, Han ZL, et al. Bile acids modified by the intestinal microbiota promote colorectal cancer growth by suppressing CD8⁺ T cell effector functions[J]. Immunity, 2024, 57(4): 876-889.e11. DOI: 10.1016/j.immuni.2024.02.014.
[27]	Jdeed G, Kravchuk B, Tikunova NV. Factors affecting phage-bacteria coevolution dynamics[J]. Viruses, 2025, 17(2): 235. DOI: 10.3390/v17020235.
[28]	Yang Y, Wang D, Li L, et al. Evolution of enteric viruses in the progression of colorectal cancer via the adenoma-carcinoma sequence pathway[J]. Virus Res, 2025, 355: 199569. DOI: 10.1016/j.virusres.2025.199569.
[29]	Gheorghe AS, Negru SM, Preda M, et al. Biochemical and metabolical pathways associated with microbiota-derived butyrate in colorectal cancer and omega-3 fatty acids implications: a narrative review[J]. Nutrients, 2022, 14(6): 1152. DOI: 10.3390/nu14061152.
[30]	Luu M, Riester Z, Baldrich A, et al. Microbial short-chain fatty acids modulate CD8⁺ T cell responses and improve adoptive immunotherapy for cancer[J]. Nat Commun, 2021, 12(1): 4077. DOI: 10.1038/s41467-021-24331-1.
[31]	Ryu TY, Kim K, Han TS, et al. Human gut-microbiome-derived propionate coordinates proteasomal degradation via HECTD2 upregulation to target EHMT2 in colorectal cancer[J]. ISME J, 2022, 16(5): 1205-1221. DOI: 10.1038/s41396-021-01119-1. pmid: 34972816
[32]	Ternes D, Tsenkova M, Pozdeev VI, et al. The gut microbial metabolite formate exacerbates colorectal cancer progression[J]. Nat Metab, 2022, 4(4): 458-475. DOI: 10.1038/s42255-022-00558-0. pmid: 35437333
[33]	Zhang QQ, Zhao Q, Li T, et al. Lactobacillus plantarum-derived indole-3-lactic acid ameliorates colorectal tumorigenesis via epigenetic regulation of CD8⁺ T cell immunity[J]. Cell Metab, 2023, 35(6): 943-960.e9. DOI: 10.1016/j.cmet.2023.04.015.
[34]	Jia D, Wang QW, Qi YD, et al. Microbial metabolite enhances immunotherapy efficacy by modulating T cell stemness in pan-cancer[J]. Cell, 2024, 187(7): 1651-1665.e21. DOI: 10.1016/j.cell.2024.02.022.
[35]	Cui WW, Guo M, Liu D, et al. Gut microbial metabolite facilitates colorectal cancer development via ferroptosis inhibition[J]. Nat Cell Biol, 2024, 26(1): 124-137. DOI: 10.1038/s41556-023-01314-6. pmid: 38168770
[36]	Mohanty I, Allaband C, Mannochio-Russo H, et al. The changing metabolic landscape of bile acids-keys to metabolism and immune regulation[J]. Nat Rev Gastroenterol Hepatol, 2024, 21(7): 493-516. DOI: 10.1038/s41575-024-00914-3. pmid: 38575682
[37]	Sun LL, Cai J, Gonzalez FJ. The role of farnesoid X receptor in metabolic diseases, and gastrointestinal and liver cancer[J]. Nat Rev Gastroenterol Hepatol, 2021, 18(5): 335-347. DOI: 10.1038/s41575-020-00404-2. pmid: 33568795
[38]	Li ZY, Deng LJ, Cheng MT, et al. Emerging role of bile acids in colorectal liver metastasis: from molecular mechanism to clinical significance (review)[J]. Int J Oncol, 2025, 66(3): 24. DOI: 10.3892/ijo.2025.5730.
[39]	Li CH, Xing X, Li MZ, et al. Bile acids produced by gut microbiota activate TGR5 to promote colorectal liver metastasis progression by inducing MDSCs infiltration in liver[J]. Int Immunopharmacol, 2025, 158: 114829. DOI: 10.1016/j.intimp.2025.114829.
[40]	Kubota H, Ishizawa M, Kodama M, et al. Vitamin D receptor mediates attenuating effect of lithocholic acid on dextran sulfate sodium induced colitis in mice[J]. Int J Mol Sci, 2023, 24(4): 3517. DOI: 10.3390/ijms24043517.
[41]	Zhang H, Xu HJ, Zhang CL, et al. Ursodeoxycholic acid suppresses the malignant progression of colorectal cancer through TGR5-YAP axis[J]. Cell Death Discov, 2021, 7(1): 207. DOI: 10.1038/s41420-021-00589-8. pmid: 34365464

肠道微生态与结直肠癌发生发展的关系

Relationship between intestinal microecology and the occurrence and progression of colorectal cancer

RichHTML

PDF

可视化

摘要/Abstract

引用本文

使用本文

参考文献 41

相关文章 15

编辑推荐

Metrics

本文评价

[1]	孙晓宁, 何盼, 王宪, 姚淑娟. 卵巢癌中癌相关成纤维细胞的免疫调节机制与临床意义[J]. 国际肿瘤学杂志, 2026, 53(6): 376-380.
[2]	刘鲁嘉, 王玉坤, 郑海涛. 肠道菌群与甲状腺癌因果关系的研究[J]. 国际肿瘤学杂志, 2026, 53(4): 193-200.
[3]	刘凯, 廖智鹏, 杜爱超, 董志强. 微嵌合体在恶性肿瘤发生发展中的作用[J]. 国际肿瘤学杂志, 2026, 53(4): 229-233.
[4]	海亚楠, 鲍文芳, 申屠航笑, 陈敬德. dMMR/MSI-H转移性结直肠癌免疫治疗耐药机制及耐药后治疗进展[J]. 国际肿瘤学杂志, 2025, 52(9): 598-602.
[5]	陈俊, 唐丹丹, 周雨馨, 谭玉婷, 李泓澜, 徐群, 项永兵. 1990—2021年中国中青年结直肠癌疾病负担时间趋势分析[J]. 国际肿瘤学杂志, 2025, 52(8): 508-516.
[6]	吴鑫, 任海朋. KRAS^G12C抑制剂在晚期结直肠癌治疗中的研究进展[J]. 国际肿瘤学杂志, 2025, 52(8): 538-542.
[7]	王勇, 乌新林. 结直肠癌肝转移的相关分子机制[J]. 国际肿瘤学杂志, 2025, 52(6): 388-391.
[8]	郭海洋, 洪永刚, 郝立强. 铁死亡在结直肠癌中的作用及研究进展[J]. 国际肿瘤学杂志, 2025, 52(5): 319-324.
[9]	. 结直肠癌筛查与早诊早治方案（2024年版）[J]. 国际肿瘤学杂志, 2025, 52(4): 195-196.
[10]	文英美, 夏锦雄, 王园园, 姚颐. 放疗对抗肿瘤免疫的影响：从基础到临床[J]. 国际肿瘤学杂志, 2025, 52(4): 231-236.
[11]	王逸, 王强力, 张甲, 杨懿瑾, 王盛. 结直肠癌肝转移患者组织中SUCNR1和YBX1的表达与临床病理特征及预后的关系[J]. 国际肿瘤学杂志, 2025, 52(3): 152-157.
[12]	詹海峰, 谭子煊, 王文学, 耿嘉蔚. 节律基因在结直肠癌发生发展和时辰疗法中的研究进展[J]. 国际肿瘤学杂志, 2025, 52(1): 60-64.
[13]	韦伟, 蔡曌颖, 钱亚云. 通关藤联合XELOX方案促进人结直肠癌HCT116细胞双硫死亡的作用[J]. 国际肿瘤学杂志, 2024, 51(9): 545-555.
[14]	詹海峰, 王文学, 耿嘉蔚. 晚期结直肠癌精准分子靶向治疗研究进展[J]. 国际肿瘤学杂志, 2024, 51(9): 601-605.
[15]	李志伟, 翟春宝. 中药多酚类成分抗结直肠癌作用研究进展[J]. 国际肿瘤学杂志, 2024, 51(8): 526-531.